Henan Newland Pharmaceutical Co. Ltd. A

Xintiandi released its 2026 interim report. First-half net profit attributable to the parent was 60.77 million yuan, down 22.1% year on year, while operating revenue was 397 million yuan, up 10.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 54.72 million yuan, down 23.8% year on year. Net operating cash flow was 6.98 million yuan, down 79.0% year on year. Earnings per share were 0.155 yuan. In the second quarter, operating revenue was 190 million yuan, up 36.7% year on year, and net profit attributable to the parent was 24.67 million yuan, up 14.9% year on year. As of the end of the second quarter, total assets were 1.754 billion yuan, down 1.4% from the end of the previous year, and net assets attributable to the parent were 1.534 billion yuan, down 1.1% from the end of the previous year. The company said its main business has not undergone major changes, and it is implementing a new strategy-driven development model to build a modern platform-based company. In the pharmaceutical intermediates business, the main products are the levophenylglycine series and the p-toluenesulfonic acid series. In the active pharmaceutical ingredients business, 15 products have been approved for registration in China, and the formulations business is also advancing integrated development.